Heather A. Lillemoe

Heather A. Lillemoe

Auto-generated profile, based on publicly available information

Heather A. Lillemoe

Department of Breast Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2024 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
HCHaydee Del Calvo
Haydee Del Calvo
YWYun Wu
Yun Wu
HLHeather Y. Lin
Heather Y. Lin
ENElise F. Nassif
Elise F. Nassif
MZMaria A. Zarzour
Maria A. Zarzour
HLHeather A. Lillemoe
Heather A. Lillemoe

5 June 2019 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
HLHeather A. Lillemoe
Heather A. Lillemoe
CSChristopher P. Scally
Christopher P. Scally
CACelia L. Adams
Celia L. Adams
BBBrian K. Bednarski
Brian K. Bednarski
CBCharles M. Balch
Charles M. Balch
EGElizabeth G. Grubbs
Elizabeth G. Grubbs

7 October 2022 in Surgery
Verified
Journal Article
Closed access
HLHeather A. Lillemoe
Heather A. Lillemoe
DHDavid N. Hanna
David N. Hanna
NBNaira Baregamian
Naira Baregamian
CSCarmen C. Solórzano
Carmen C. Solórzano
KTKyla P. Terhune
Kyla P. Terhune
CKColleen M. Kiernan
Colleen M. Kiernan

26 November 2024 in Molecular Carcinogenesis
Verified
Journal Article
Open access
KTKatarzyna Tomczak
Katarzyna Tomczak
MPManishkumar S. Patel
Manishkumar S. Patel
ABAngela D. Bhalla
Angela D. Bhalla
CPChristine Peterson
Christine Peterson
SLSharon M. Landers
Sharon M. Landers
KTKeila E. Michael Torres
Keila E. Michael Torres
Malignant peripheral nerve sheath tumor (MPNST) development is characterized by an altered DNA methylation landscape, which presents a promising area for developing MPNST‐specific biomarkers for screening patients with NF1. Genome‐wide DNA methylation profiling of a cohort of 13 patients with MPNST (29 samples of tumor and adjacent neurofibroma tissues) and of NF1‐MPNST cell lines was performed to identify and validate candidate MPNST‐specific CpG sites (CpGs). A logistic regression prediction model was constructed to select MPNST‐specific CpGs distinct from adjacent neurofibromas and normal tissues. To test if hypermethylation at selected CpGs can also be detected in plasma from patients with MPNST, cfMBD‐seq was applied to profile the cfDNA methylome of blood from patients with MPNST and NF1. Based on stringent feature‐selection criteria and predictive modeling, we identified 73 candidate MPNST‐specific CpGs (67 with unique CpG island locations) that reliably discriminated MPNSTs from neurofibromas. Validation of five candidate biomarkers confirmed successful MPNST detection (sensitivity: > 88%, specificity: > 91%) in tissues. In plasma samples, 63 of 67 selected genomic regions had greater than 1.2‐fold higher methylation in patients with MPNST than those with NF1. Further, we identified 15 CpG islands that consistently separated plasma from patients with confirmed MPNST diagnosis from plasma of individuals with NF1 without a diagnosis of malignant transformation (FDR < 0.1). Our findings confirmed a unique hypermethylation pattern present during malignant transformation. This study highlights the potential to be investigated further as biomarkers in clinical settings for early MPNST detection in patients with NF1.

6 July 2020 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
HLHeather A. Lillemoe
Heather A. Lillemoe
TNTimothy E. Newhook
Timothy E. Newhook
TAThomas A. Aloia
Thomas A. Aloia
EGElizabeth G. Grubbs
Elizabeth G. Grubbs
GCGeorge J. Chang
George J. Chang
CTChing-Wei D Tzeng
Ching-Wei D Tzeng

14 November 2022 in Journal of the American College of Surgeons
Verified
Journal Article
Closed access
HLHeather A Lillemoe
Heather A Lillemoe
JWJelani K Williams
Jelani K Williams
MTMediget K Md Teshome
Mediget K Md Teshome
LZLinda Bs Zheng
Linda Bs Zheng
AFAmanda B Francescatti
Amanda B Francescatti
EAElliot A Asare
Elliot A Asare
The purpose of this article is to review the objectives of the American College of Surgeons Commission on Cancer Operative Standards with a specific focus on Standard 5.5, which pertains to curative intent wide local excision of primary cutaneous melanoma lesions. We review the details and rationale of the standard itself, including its requirement to include specific elements and responses in synoptic format in operative reports.